Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. Patients who met eligibility criteria were able to continue ganaxolone treatment during a 24-week extension to the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. Mental health treatment is big business, with the global antidepressant drug market valued at over $13 billion in 2016. Threat to Patient Access in Oregon. The Race to Patent Psilocybin.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. CONVENTIONAL TREATMENT. One of the goals of treating epilepsy is to allow people to continue to live functional and fulfilling life’s epilepsy treatment. CANNABIS AS A POTENTIAL TREATMENT.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Veriheal

SEPTEMBER 23, 2021

Note: Veriheal does not support illegally consuming therapeutic substances such as Iboga but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? At this time, there is little in the way for combat-related PTSD treatment specifically. Let’s find out. .

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Eric Rahn, Managing Director. For more information, visit [link].

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

JANUARY 17, 2022

The processes outlined in this patent application are positioned to enable scalable manufacturing because they require fewer synthetic steps than current methods, utilize cost effective and readily available starting materials, and leverage chemical manufacturing processes that are already standard practice in the pharmaceutical industry.

Research and Development 52

Research and Development Pharmaceutical Access Medicine 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. About RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Veriheal

JULY 22, 2021

You may have wondered what the impact of cannabis legalization would be on the illicit market and the drugs accessed there. Well, a recent study found that one of the implications involves impacting the prices in the unlicensed cannabis market as well as the illicit pharmaceutical market. increase in oxycodone prices, and a 5.1%

Legalization 52

Legalization Pharmaceutical Data Recreational 52

Veriheal

APRIL 24, 2023

The body of scientific evidence supporting the use of psychedelics in the treatment of PTSD, addiction, major depressive disorder, and various other mental health disorders continues to grow. However, despite the mounting data supporting their efficacy, the precise mechanism of action for psychedelics remains a mystery.

Research and Development 77

Research and Development Treatment Conditions Therapy 77

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

AUGUST 12, 2021

Since 2013, medicinal cannabis has been legalized in the Czech Republic due to the amendment to the Act on pharmaceuticals, otherwise known as Act No. With medical research indicating that using the plant provides significant medical benefits, the Czech Chamber of Deputies suggested a revision to the government’s Act on pharmaceuticals.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Law School. FSA/Dep Care.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. physicians began over-prescribing opioids like oxycodone due to reassurance from pharmaceutical companies that they were not addictive—which patients quickly discovered to be untrue.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

SpeedWeed

MARCH 13, 2021

Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. . View original article.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JUNE 7, 2019

The use of pharmaceutical cannabinoid products in Singapore comes under strict frameworks and regulations and does not diminish the country’s zero-tolerance position against drugs, the Home Affairs and Health ministries have said. The Straits Times Reports. Cannabinoids are chemical compounds found in the cannabis plant.

Pharmaceutical 40

Pharmaceutical Cannabinoids Safety Data 40

Cannabis Law Report

JUNE 8, 2022

Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access. Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board. Published: Jun 07, 2022. His experience spans therapeutic areas, with significant depth across major areas of neuroscience.

Therapy 52

Therapy Treatment Access Patients 52

PrestoDoctor

SEPTEMBER 6, 2023

One of the primary reasons for this shift is the growing acceptance and accessibility of cannabis as an alternative pain management option. Many individuals prefer the idea of using a plant-based substance rather than relying on synthetic pharmaceuticals. This makes it an attractive alternative to prescription medications.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

NOVEMBER 14, 2019

Australia’s westernmost state is making it easier for patients to access medical cannabis. When considering many using medicinal cannabis products have serious illnesses and are sometimes financially strained, the previous access regime unnecessarily added a number of months and additional costs to the process.”

Patients 45

Patients Access Medicine Pharmaceutical 45

CannaMD

NOVEMBER 6, 2019

And so, in light of America’s ongoing struggle with a sweeping opioid crisis of addiction and overdose deaths, it makes sense that there is a growing interest both among the public and the medical community in the possibilities of medical marijuana as an alternative to pharmaceuticals for pain management. percent, respectively.

Marijuana 87

Marijuana Patients Clinical Trials Data 87

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. In other cases, CBDA products — or a mixture of CBD and CBDA — may be preferable, if for instance treatments with high doses of CBD have been unsuccessful for you.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

DECEMBER 17, 2021

Zygel (ZYN002; Cannabidiol): Zynerba Pharmaceuticals. Zygel (ZYN002), developed by Zynerba Pharmaceuticals, is the first and only pharmaceutically produced Cannabidiol (CBD). The drugs which are in pipeline include: Zygel (ZYN002): Zynerba Pharmaceuticals. Access and Reimbursement Scenario. Deletion Syndrome.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JUNE 9, 2021

MAPS is committed to bringing these healing modalities to the world and providing them in such a way that communities that most need mental health resources have access to them. MAPS strives to continually improve upon the supportive, equitable, and accessible work environment. Pharmaceutical or cannabis industry experience a plus.

Research and Development 76

Research and Development Compliance Compliance Education 76

Cannabis Law Report

DECEMBER 1, 2019

Suffering from refractory epilepsy, the girl failed to respond to therapies and had exhausted all currently registered medications for treatment, the Ministry of Home Affairs (MHA) told The Sunday Times. However, Prof Chan added that Epidiolex would not be the first line of epilepsy treatment.

Epilepsy 59

Epilepsy Cannabinoids Therapy Treatment 59

Sensi Seeds

JANUARY 4, 2019

Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). It allows patients to have access to medicinal cannabis without danger of being criminalized. Context of the Medicinal Cannabis Situation.

Medicine 75

Medicine Research and Development Patients Programs 75

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97